Form 4: Arcutis Biotherapeutics CEO Todd Watanabe Sells Shares Under 10b5-1 Trading Plan
SEC Form 4 Filing
Arcutis Biotherapeutics CEO Todd Franklin Watanabe sold shares of the company's common stock on March 24 and 25, 2025, under a pre-arranged 10b5-1 trading plan.
Summary
- Todd Franklin Watanabe, CEO of Arcutis Biotherapeutics, sold 1,500 shares of common stock on March 24, 2025, at a weighted average price of $17.5213.
- He then sold 2,171 shares on March 25, 2025, at a weighted average price of $17.564.
- These transactions were executed under a 10b5-1 trading plan adopted on June 14, 2024, with a plan end date of September 30, 2025.
- Following these sales, Watanabe directly owns 925,243 shares of Arcutis Biotherapeutics common stock.
- Watanabe also has indirect ownership through various trusts and an LLC.
- He disclaims beneficial ownership of shares held by these entities except to the extent of his pecuniary interest.
Sentiment
Score: 5
Explanation: The document is a standard SEC Form 4 filing, indicating insider trading activity under a pre-arranged plan. It is neutral in sentiment as it simply reports transactions.
Industry Context
Sales by company executives are a normal part of corporate governance. The use of a 10b5-1 trading plan allows insiders to sell shares over a period of time without being accused of trading on inside information.
Stakeholder Impact
- Shareholders may react to the news of the CEO selling shares, although the existence of a 10b5-1 plan mitigates concerns about insider information.
Key Dates
| Date | Description |
|---|---|
| 2024-06-14 | Date of adoption of the 10b5-1 trading plan. |
| 2025-03-24 | Date of first reported transaction (sale of 1,500 shares). |
| 2025-03-25 | Date of second reported transaction (sale of 2,171 shares). |
| 2025-03-26 | Date of signature on the Form 4 filing. |
| 2025-09-30 | End date of the 10b5-1 trading plan. |
Keywords
Arcutis Biotherapeutics, ARQT, Todd Franklin Watanabe, CEO, share sale, Form 4, 10b5-1 trading plan, insider trading
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.